Gene · 55165
Papers1,450
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 1,450
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Diabetes-associated breast cancer is molecularly distinct and shows a DNA damage repair deficiency. | JCI Insight | 2023 | 37906280 | PubTator, text mining | PubMed |
| CEP55 as a Promising Immune Intervention Marker to Regulate Tumor Progression: A Pan-Cancer Analysis with Experimental Verification. | Cells | 2023 | 37887301 | PubTator, text mining | PubMed |
| Insights into the function of ESCRT and its role in enveloped virus infection. | Front Microbiol | 2023 | 37869652 | PubTator, text mining | PubMed |
| Analysis of genetic biomarkers, polymorphisms in ADME-related genes and their impact on pharmacotherapy for prostate cancer. | Cancer Cell Int | 2023 | 37858151 | PubTator, text mining | PubMed |
| Advanced stage, high-grade primary tumor ovarian cancer: a multi-omics dissection and biomarker prediction process. | Sci Rep | 2023 | 37828118 | PubTator, text mining | PubMed |
| An immune and epigenetics-related scoring model and drug candidate prediction for hepatic carcinogenesis via dynamic network biomarker analysis and connectivity mapping. | Comput Struct Biotechnol J | 2023 | 37817777 | PubTator, text mining | PubMed |
| Comprehensive proteomic analysis of JC polyomavirus-infected human astrocytes and their extracellular vesicles. | Microbiol Spectr | 2023 | 37815349 | PubTator, text mining | PubMed |
| Recent advances in the understanding of cilia mechanisms and their applications as therapeutic targets. | Front Mol Biosci | 2023 | 37780208 | PubTator, text mining | PubMed |
| SYT7 is a key player in increasing exosome secretion and promoting angiogenesis in non-small-cell lung cancer. | Cancer Lett | 2023 | 37774826 | PubTator, text mining | PubMed |
| Long non-coding RNA AC099850.4 correlates with advanced disease state and predicts worse prognosis in triple-negative breast cancer. | Front Med (Lausanne) | 2023 | 37727755 | PubTator, text mining | PubMed |
| Various LncRNA Mechanisms in Gene Regulation Involving miRNAs or RNA-Binding Proteins in Non-Small-Cell Lung Cancer: Main Signaling Pathways and Networks. | Int J Mol Sci | 2023 | 37686426 | PubTator, text mining | PubMed |
| A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma. | Front Pharmacol | 2023 | 37670938 | PubTator, text mining | PubMed |
| Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches. | Front Genet | 2023 | 37662839 | PubTator, text mining | PubMed |
| A systematic approach identifies p53-DREAM pathway target genes associated with blood or brain abnormalities. | Dis Model Mech | 2023 | 37661832 | PubTator, text mining | PubMed |
| Uncovering Novel Roles of miR-122 in the Pathophysiology of the Liver: Potential Interaction with NRF1 and E2F4 Signaling. | Cancers (Basel) | 2023 | 37627157 | PubTator, text mining | PubMed |
| Amorphous silica nanoparticles cause abnormal cytokinesis and multinucleation through dysfunction of the centralspindlin complex and microfilaments. | Part Fibre Toxicol | 2023 | 37608338 | PubTator, text mining | PubMed |
| Machine learning-based on cytotoxic T lymphocyte evasion gene develops a novel signature to predict prognosis and immunotherapy responses for kidney renal clear cell carcinoma patients. | Front Immunol | 2023 | 37600786 | PubTator, text mining | PubMed |
| CEACAM1 as a molecular target in oral cancer. | Aging (Albany NY) | 2023 | 37589542 | PubTator, text mining | PubMed |
| Identification of survival-associated biomarkers based on three datasets by bioinformatics analysis in gastric cancer. | World J Clin Cases | 2023 | 37584004 | PubTator, text mining | PubMed |
| Unraveling the Complex Web of Mechanistic Regulation of Versatile NEDD4 Family by Non-Coding RNAs in Carcinogenesis and Metastasis: From Cell Culture Studies to Animal Models. | Cancers (Basel) | 2023 | 37568787 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/55165/papers?page=8